CPRX Q4 2025 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$153M+7.6% YoY

Gross Profit

$139M90.8% margin

Operating Income

$62M40.5% margin

Net Income

$53M34.5% margin

EPS (Diluted)

$0.40

QoQ Revenue Growth

+2.8%

Cash Flow

Operating Cash Flow

$45M

Free Cash Flow

$45M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$150M

Stockholders' Equity

$954M

Cash & Equivalents

$709M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$153M	$142M	+7.6%
Gross Profit	$139M	$120M	+15.3%
Operating Income	$62M	$63M	-1.6%
Net Income	$53M	$56M	-5.8%

Revenue Segments

Product Revenue Net

$153M100%

License And Other Revenue

$111,0000%